| Literature DB >> 32164766 |
Anthony Ayodeji Adegoke1,2,3, Chibuzor Ezinne Madu4, Olayinka Ayobami Aiyegoro5,6, Thor Axel Stenström4, Anthony Ifeanyi Okoh5,7.
Abstract
BACKGROUND: The World Health Organization (WHO) recently classified Enterobacteriaceae resistance to third-generation cephalosporin into the group of pathogens with critical criteria for future research.Entities:
Keywords: Beta-lactamase genes; Carbapenem; Cefotaxime; Ciprofloxacin; Wastewater; bla CTX; bla OXA-1
Mesh:
Substances:
Year: 2020 PMID: 32164766 PMCID: PMC7068970 DOI: 10.1186/s13756-020-0702-4
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Wastewater parameters from the WWTP
| Wastewater parameters | Influent (mg/L) | Effluent (mg/L) |
|---|---|---|
| COD (total) | 250–1100 | 75 |
| Total-N | 10–60 | 0–25 |
| NH4-N | 10–60 | 0–25 |
| Total-P | 20–80 | 0–10 |
| NO3-N (Effluent) | N/A | 0–10 |
| Suspended solids (Effluent) | N/A | 25 μS/cm |
N/A means Not Available
Primer sequences and amplicon size of PCR-amplified gene targets
| Target species | Gene target | Primer sequence 5′–3′ | Amplicon size (bp) |
|---|---|---|---|
| CTGGAAGAGGCTAGCCTGGACGAG | 366 | ||
| AAAATCGGCACCGGTGGAGCGATC |
Primer sequences, genes for beta-lactamase and the expected amplicon sizes
| Group | Gene name | Primer sequence (5′–3′) | Expected amplicon size (bp) |
|---|---|---|---|
| ESBLS genes | GTCGCCGCATACACTATTCTCA | 258 | |
| CGCTCGTCGTTTGGTATGG | |||
| CGGGAGGCAGACTGGGTGT | 381 | ||
| TCGGCTCGGTACGGTCGA | |||
| GCCTTGACCGCTGGGAAAC | 319 | ||
| GGCGTATCCCGCAGATAAAT | |||
| Carbapenemase genes | GATGGTGTTTGGTCGCATA | 390 | |
| CGAATGCGCAGC | |||
| TTCTGTTGTTTGGGTTTCGC | 190 | ||
| ACGCAGGAATTGAATTTGTTC | |||
| GCTTCCCACTGTGCAGCTCATTC | 213 | ||
| CGCCCAACTCCTCAGCAACAATTG | |||
| GGTGCATGCCCGGTGAAATC | 660 | ||
| ATGCTGGCCTTGGGGAACG |
Primer sequences and expected amplicon sizes of the pathogenic Strains of E. coli (Pathotyping)
| Target strain | Gene Target | Primer Sequence (5′–3′) | Amplicon Size (bp) |
|---|---|---|---|
| EAEC | AGA CTC TGG CGA AAG ACT GTA TC | 194 | |
| ATG GCT GTC TGT AAT AGA TGA GAA C | |||
| EPEC | CTG AAC GGC GAT TAC GCG AA | 917 | |
| GAC GAT ACG ATC CAG | |||
| ETEC | GGC GAC AGA TTA TAC CGT GC | 450 | |
| CGG TCT CTA TAT TCC CTG TT | |||
| ATTTTTCTTTCTGTATTGTCTT | 190 | ||
| CACCCGGTACAAGCAGGATT | |||
| EIEC | CTGGTAGGTATGGTGAGG | 320 | |
| CCAGGCCAACAATTATTTCC |
Fig. 1a Count [Log10 (CFU/mL)] of Presumptive Total E. coli (TEc) and Cefotaxime Resistant E. coli (CREc) in summer Influent samples (b) Count [Log10 (CFU/mL)] of other Coliforms and Cefotaxime Resistant Coliforms in summer influent samples. Legend: Inf SR-3 NA = influent sample at sampling occasion 3 without antibiotic, Inf SR-3 A4 = influent sample at sample occasion 3 with 4 mg/L of cefotaxime antibiotic, Inf SR-3 A8 = influent sample 3 with 8 mg/L of cefotaxime antibiotic; Inf SR-2 NA = influent sample at sampling occasion 2 without antibiotic; Inf SR-2 A4 = influent sample at sample occasion 2 with 4 mg/L of cefotaxime antibiotic; Inf SR-2 A8 = influent sample 2 with 8 mg/L of cefotaxime antibiotic; Inf SR-1 NA = influent sample at sampling occasion 1 without antibiotic; Inf SR-1 A4 = influent sample at sample occasion 1 with 4 mg/L of cefotaxime antibiotic; Inf SR-1 A8 = influent sample 1 with 8 mg/L of cefotaxime antibiotic. Figure 1: c Count [Log10 (CFU/mL)] of Presumptive Total E. coli (TEc) and Cefotaxime Resistant E. coli (CREc) in Winter Influent samples (d) Count [Log10 (CFU/mL)] of other Coliforms and Cefotaxime Resistant Coliforms in Winter Influent samples. e Count [Log10 (CFU/mL)] of E. coli and other coliforms in effluent samples. Legend: Inf SR-4 NA = influent sample at sampling occasion 4 without antibiotic, Inf SR-4 A4 = influent sample at sample occasion 4 with 4 mg/L of cefotaxime antibiotic; Inf SR-4A8 = influent sample during sample occasion 4 with 8 mg/L of cefotaxime antibiotic; Inf SR-4 NA = influent sample at sampling occasion 4 without antibiotic; Inf SR-5 A4 = influent sample at sample occasion 5 with 4 mg/L of cefotaxime antibiotic; Inf SR-5 A8 = influent sample during sample occasion 5 with 8 mg/L of cefotaxime antibiotic; Eff SR-1 NA = effluent sample occasion 1 for E. coli without antibiotic supplementation; Eff SR-2 NA = effluent sample occasion 2 for E. coli without antibiotic supplementation; Eff SR-3 NA = effluent sample occasion 3 for E. coli without antibiotic supplementation; Eff SR-1 O-NA = effluent sample occasion 1 for other coliforms without antibiotic supplementation etc.
Susceptibility profile of cefotaxime resistant E. coli to other selected antibiotics
| Antibiotics | Percentage of isolates | ||
|---|---|---|---|
| R | I | S | |
| Amoxicillin-clavulanic acid | 35.3 | 52.9 | 11.8 |
| aColistin sulphate | 76.5 | 11.8 | 5.9 |
| Meropenem | 0 | 11.8 | 88.2 |
| Ciprofloxacin | 47.1 | 23.5 | 29.4 |
| Trimethoprim-sulphamethoxazole | 81.3 | 0 | 18.8 |
| bGentamicin | 87.5 | 12.5 | 0 |
| Tetracycline | 56.3 | 0 | 37.5 |
| Nitrofurantoin | 37.5 | 25 | 37.5 |
R Resistance, I Intermediate, S Sensitive, n = 51; an = 36; bn = 48
Fig. 2MAR Index of the cefotaxime resistant E. coli and their percentage of isolates
Selected beta-lactamase genes in cefotaxime resistant E. coli from wastewater treatment plants
| Group | Beta-lactamase genes | % |
|---|---|---|
ESBLs genes (A) | 52.6 | |
| 84.2 | ||
| 0 | ||
| 36.8 | ||
Carbapenem genes (B) | 15.8 | |
| 57.9 | ||
| 0 | ||
| 15.8 | ||
| 15.8 | ||
| 10.5 | ||
A + B | 10.5 | |
| 36.8 | ||
| 10.5 | ||
| 15.8 | ||
| 52.6 | ||
| 15.8 |
Fig. 3Pathotypes of selected cefotaxime resistant E. coli (n = 30)